Brokerages expect POINT Biopharma Global Inc. (NASDAQ:PNT) to post earnings per share of ($0.17) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for POINT Biopharma Global’s earnings, with estimates ranging from ($0.30) to ($0.10). The company is scheduled to issue its next earnings results on Friday, November 12th.
On average, analysts expect that POINT Biopharma Global will report full year earnings of ($0.59) per share for the current financial year, with EPS estimates ranging from ($0.97) to ($0.37). For the next year, analysts forecast that the business will post earnings of ($0.83) per share, with EPS estimates ranging from ($1.39) to ($0.51). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for POINT Biopharma Global.
POINT Biopharma Global (NASDAQ:PNT) last posted its quarterly earnings data on Thursday, August 12th. The company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.01.
Shares of PNT opened at $8.08 on Monday. POINT Biopharma Global has a 12 month low of $6.64 and a 12 month high of $18.08. The stock’s 50-day moving average is $9.06.
POINT Biopharma Global Company Profile
POINT Biopharma Global Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of radioligand therapies for the treatment of cancer. Its products include PNT2001, a PSMA radioligand that is in preclinical studies for early stage prostate cancer treatment; PNT2002, which is in Phase 3 studies to evaluate superiority to the standard of care in mCRPC patients; PNT2003, a somatostatin-targeted radioligand therapy that is in Phase 3 trials for the treatment of patients with somatostatin receptor-positive neuroendocrine tumors; and PNT2004, a radioligand that targets fibroblast activation protein-a.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for POINT Biopharma Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POINT Biopharma Global and related companies with MarketBeat.com's FREE daily email newsletter.